

PRESS RELEASE
30 September 2010



BioInvent communicates next stage of TB-403 development programme in partnership with Roche

Clarification follows market speculation and stock price movement

Lund, Sweden – 30 September 2010 – Following stock price movement on 29 September, BioInvent International AB (OMXS: BINV) wishes to communicate the status of its TB-403 (RG7334) programme, in development with Roche.

Roche plans to initiate the next phase of TB-403 development in early 2011. A phase Ib/II trial of TB-403 in combination with Avastin in Glioblastoma Multiforme patients will commence Q1 2011.

A DCE-MRI imaging study of TB-403 that was commenced by Roche earlier this year has been stopped as per protocol.

-- END --

Notes to Editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA.

More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB

Svein Mathisen
President & CEO
Tel: +46 (0)46-286 85 67
Mobile: +46 (0)708-97 82 13
E-mail: svein.mathisen@bioinvent.com

Cristina Glad
Executive Vice President
Tel: +46 (0)46-286 85 51
Mobile: +46 (0)708-16 85 70
E-mail: cristina.glad@bioinvent.com

College Hill (media enquiries)
Katja Toon, Justine Lamond, Anastasios Koutsos
Tel: +44 (0)20 7866 7857
E-mail: bioinvent@collegehill.com
Erik Clausen (US)
Tel: +1 415-230-5385
E-mail: erik.clausen@collegehill.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263,

Address: Sölvegatan 41

Mailing address: SE-223 70 LUND

Tel: +46 (0)46 286 85 50

info@bioinvent.com

www.bioinvent.com

Legal disclaimer

This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.20 a.m. CET, on 30 September, 2010.